Switch therapy in full-term neonates with presumed or proven bacterial infection

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 68-73

  Manzoni, Paolo ^a   Esposito, S ^b   Gallo, E ^a   Gastaldo, L ^a   Farina, D ^a   Principi, N ^b  

^a Hospital St Anna   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antibiotic therapy; Bacterial infection; Cefpodoxime proxetil; Neonatal infections; Newborns; Switch therapy

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFPODOXIME; SULTAMICILLIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BACTERIAL INFECTION; CASE CONTROL STUDY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; INFECTION CONTROL; LENGTH OF STAY; MALE; MULTIPLE CYCLE TREATMENT; NEWBORN CARE; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; SINGLE DRUG DOSE;

EID: 63049100464     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.68     Document Type: Article

References (21)

1. Klein JO, Remington JS. Current concepts of infections of the fetus and newborn infants. In: Remington JS, Klein JO (eds) Textbook of Infectious Diseases of the Fetus and Newborn Infant. 5th ed. Philadelphia, PEN: W.B. Saunders Company: pp. 1-23.
2. Kaftan H, Kinney JS. Early onset neonatal bacterial infections. Semin Perinatol 1998; 22: 15-24.
3. Jeffrey S, Gerdes MD. Diagnosis and management of bacterial infections in the neonate. Pediatr Clin North Am 2004; 51: 939-959.
4. de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fet Neonat Med 2005; 10: 185-194.
5. Heimann GG. Enteral absorption and bioavailability in children in relation to age. Eur J Clin Pharmacol 1980; 18: 43-50.
6. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29: 561-565.
7. Vogtlander NP, Van Kasteren ME, Natsch S, Kullberg BJ, Hekster YA, Van der Meer JW. Improving the process of antibiotic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy. Arch Intern Med 2004; 164: 1206-1212.
8. Dagan R, Syrogiannopoulos G, Ashkenazi S, Engelhard D, Einhorn M, Gatzola-Karavelli M, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl 3: 43-51.
9. Gollin G, Abarbanell A, Moores D. Oral antibiotics in the management of perforated appendicitis in children. Am Surg 2002; 68: 1072-1074.
10. Frampton JE, Brogden RN, Langtry HD, Buckley MM. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 889-917.
11. Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients. Paediatr Drugs 2001; 3: 137-158.
12. Richardson DK, Corcoran JD, Escobar GJ, Lee SK, for the Canadian NICU Network, The Kaiser Permanente Neonatal Minimum Data Set Wide Area Network, The SNAP-II Study Group. SNAP-II and SNAPPE-II: simplified newborn illness severity and mortality risk scores. J Pediatr 2001;138:92-100.
13. Gras-Le Guen C, Boscher C, Godon N, Caillon J, Nguyen JM, Kergueris MF, et al. Therapeutic amoxicillin levels achieved with oral administration in term neonates. Eur J Clin Pharmacol 2007; 63: 657-662.
14. Chirico G, Cortinovis S, Fonte C, Giudici G. Bacterial sepsis. J Chemother 2007; 19 Suppl. 2: 28-30.
15. Allegaert K, Verbesselt R, Naulaers G, van den Anker M, Debeer A, de Hoon J. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008; 63: 16-24.
16. Kearns GL, Abdel-Rahman SM, Jacobs RF. Cefpodoxime pharmacokinetics in children: effect of food. Pediatr Infect Dis J 1998; 17: 799-804.
17. Carrillo NA, Giguère S, Gronwall RR, Brown MP, Merritt KA, O'Kelley JJ. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory concentration of the drug against common bacterial pathogens of horses. Am J Vet Res 2005; 66: 30-35.
18. Borin MT, Ferry JJ, Forbes KK, Hughes GS. Pharmacokinetics of cefpodoxime proxetil in healthy young and elderly volunteers. J Clin Pharmacol 1994; 34: 774-781.
19. Tremblay D, Dupront A, Ho C, Coussediere D, Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother. 1990; 26 Suppl E: 21-28.
20. Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol 1991; 31: 1137-1145.
21. Brown SA, Boucher JF, Hubbard VL, Prough MJ, Flook TF. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs. J Vet Pharmacol Ther 2007; 30: 320-326.